The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox).
Michael O'Connell
No relevant relationships to disclose
Mark Lee
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Margarita Lopatin
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Greg Yothers
No relevant relationships to disclose
Kim Clark-Langone
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Carl Millward
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Soonmyung Paik
No relevant relationships to disclose
Saima Sharif
No relevant relationships to disclose
Steven Shak
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Norman Wolmark
No relevant relationships to disclose